|Articles|April 1, 1997

April 1997
Volume 3
Issue 4

Use of Ineffective or Unsafe Medications Among Members of a Medicare HMO Compared to Individuals in a Medicare Fee-for-Service Program

Author(s)Robert Futterman, PhD, Howard Fillit, MD, John L. Rogleri, MD

Download PDF: Use of Ineffective or Unsafe Medications Among Members of a Medicare HMO Compared to Individuals in a Medicare Fee-for-Service Program

Articles in this issue

about 29 years ago

Article

Differences in Physician Compensation for Cardiovascular Services by Age, Sex, and Race

about 29 years ago

Article

Consideration in Pharmaceutical Conversion: Focus on Antihistamines

about 29 years ago

Article

Issues in the Measurement of Satisfaction with Treatment

about 29 years ago

Article

Improving Clinician Acceptance and Use of Computerized Documentation of Coded Diagnosis

about 29 years ago

Article

HMOs and the Efficiency of Healthcare Delivery

about 29 years ago

Article

Randomized Trial of Zileuton in Patients with Moderate Asthma: Effect of Reduced Dosing Frequency and Amounts on Pulmonary Function and Asthma Symptoms

about 29 years ago

Article

Abdominal Aortic Aneurysm

about 29 years ago

Article

Reducing Malpractice Risk Through More Effective Communication

about 29 years ago

Article

Correspondence regarding, "A Cost-Effective Approach to the Use of Selective Serotonin Reuptake Inhibitors in a Veterans Affairs Medical Center"

about 29 years ago

Article

Correspondence regarding, "A Successful Tobacco Cessation Program Led by Primary Care Nurses in a Managed Care Setting"

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Use of Ineffective or Unsafe Medications Among Members of a Medicare HMO Compared to Individuals in a Medicare Fee-for-Service Program

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis